Aclaris Therapeutics ACRS Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Aclaris Therapeutics’s reported figures.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's enterprise value?
- Aclaris Therapeutics (ACRS) reported enterprise value of $427.4M in Q1 2026.
- How has Aclaris Therapeutics's enterprise value changed year-over-year?
- Aclaris Therapeutics's enterprise value increased by 210.6% year-over-year, from $137.59M to $427.4M.
- What is the long-term trend for Aclaris Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's enterprise value has grown at a -4.5% compound annual growth rate (CAGR), from $388.23M to $308.28M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.